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We would like to complete the paragraph on Adjuvants 
(page 6) in the review Vaccination in children with aller-
gies to non active vaccine components by Francheschini 
et al. [1] which was initiated by the Italian Pediatric Soci-
ety of Allergy and Immunology in 2013 and published in 
Clinical and Translational Medicine in 2015.
As mentioned in the review, aluminium (Al) salts are 
widely used as adjuvants in diphtheria-tetanus-pertussis 
(DTP) and hepatitis A and B vaccines. The list can be 
completed with pneumococcal and meningococcal con-
jugate vaccines, which today are included in the national 
vaccination schedules in most countries in Europe and 
the Americas, and also in vaccines against human papil-
loma virus (HPV) and tick-bore encephalitis (TBE).
According to the authors, the most known and frequent 
reaction to Al salts is “a palpable nodule at the injection 
site”. This sounds harmless enough—but in typical cases 
the nodules are most annoying to the child due to severe 
pruritus for a very long time [2, 3]. Besides, most children 
with persistent itching vaccination granulomas become 
sensitized against Al [4].
Itching vaccination granulomas are described since 
1960 [5] but considered very rare [6] until the 1990s 
when they were reported in 745 of 76,000 children par-
ticipating in studies on a monocomponent acellular per-
tussis vaccine in Sweden [7]. Since then, another 102 
children in Sweden who received commercial DTaP-
polio-Hib-(HepB) combinations (Infanrix®, Pentavac®) 
and/or pneumococcal vaccines (Prevenar, Synflorix) are 
described [4, 8, 9]. The vaccines were given intramuscu-
larly in three doses at 3, 5 and 12 months. In a prospective 
cohort study on 4758 toddlers the frequency of granulo-
mas was 0.63% in those who received a DTaP combina-
tion vaccine alone and 1.18% in those who received an Al 
adsorbed pneumococcal vaccine at the same time. The 
risk for granulomas increased with the number of Al-
containing vaccine doses [4].
The itching nodules appear remarkably late (months 
or even years) after the vaccination. Histopathological 
examination shows granuloma formations in which Al 
crystals can be demonstrated [10]. Clinically, pruritus is 
the dominating symptom with intense local itching in the 
vaccination area on the thigh, often causing skin altera-
tions like eczema, hypertrichosis and hyperpigmentation. 
Intensified itching and swelling of the nodules is often 
reported when the child has a cold or another infection. 
After a duration of ½–12  years (median 3–4  years) the 
nodules eventually disappear and the pruritus ceases.
In some cases nodules were mistaken as tumours lead-
ing to unnecessary anxiety, investigations and surgery 
[11, 12].
Contact allergy to aluminium was verified in 77–95% 
of children with itching vaccination granulomas by epi-
cutaneous testing with Al Chloride hexahydrate 2% and 
metallic Al (4, 7, 9). Sensitized individuals have reported 
contact dermatitis after the use of Al containing deodor-
ants, pharmaceutics (ear drops, antiseptics), sun protec-
tors, tattooing pigments and metallic aluminium [13]. 
Fortunately, and contrary to earlier belief, the sensitiza-
tion to aluminium seems to vane with time [14].
The consequences of future vaccination with Al 
adsorbed vaccines in children who once reacted with 
itching granulomas and/or contact allergy to Al is only 
partially studied. Our clinical experience so far is that 
the risk for new granulomas diminishes with time and is 
very low when the original one has vanished and the itch-
ing ceased. In case of on-going severe pruritus the next 
dose may be postponed 6–12  months. The Al allergy is 
a delayed type IV reaction not associated with increased 
risk for anaphylaxis.
We want to point out that itching granulomas are 
benign and self-limiting and no cause to refrain from 
vaccination in consideration of the risk for a serious 
infectious disease. They are poorly known but easy to 
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recognize once you are aware of them. They should be 
familiar to all health care staff working with children to 
avoid mistrust and anxiety in the parents and unneces-
sary investigations of the child.
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